Hepatotoxicity and Its Impact on Mortality in COVID-19 Patients

Hepatotoxicty in COVID-19

Authors

DOI:

https://doi.org/10.37609/srinmed.1

Keywords:

COVID-19, liver function tests, mortality, alanine aminotransferase, aspartate aminotransferase

Abstract

Objective: "COVID-19-related liver damage" can occur frequently in course of COVID-19 disease and cause significant problems. Our study aimed to investigate prevalence of liver damage due to COVID-19, its risk variables, and the effect of liver damage on course of COVID-19 and mortality.

Method: One hundred patients over eighteen years of age who were hospitalized between 01.08.2021-01.03.2022 and had positive RT-PCR tests were included in our study. Impaired liver function tests were identified as having alanine aminotransferase(ALT) and aspartate aminotransferase(AST) levels exceeding upper laboratory limits.

Results: The mean age of patients included in study was 57.9 ± 14.9 years, with 49% of them being male. In our study, we had an 8% death rate and 37% of patients had abnormal liver function tests. The presence of severe disease(p<0.001), anorexia symptoms(p=0.027), and abdominal pain(p=0.010) were significant for mortality. A prolonged hospital stay was significantly associated with death(p=0.029), with the mean length of hospital stay being 11.8 ± 4.6 days. Favipiravir use for longer than five days was associated with a substantial risk of liver damage(p=0.044) and mortality(p=0.020), while use of antibiotics in carbapenem group was associated with a significant risk of death(p=0.001). 

Conclusions: It is noteworthy that a considerable proportion of COVID-19 patients may exhibit increased liver tests, which could serve as a significant predictor and risk factor, particularly with regard to mortality. In order to properly monitor and manage COVID-19 patients, particularly those who are at risk, comprehensive measurements, including liver tests, should be carried out on a regular basis. 

References

World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Accessed on March 6, 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey

Cascella M, Rajnik M, Aleem A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Jan 9. In: StatPearls [Internet].

Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020 Jun; 40(6): 1278-1281.

Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021 Feb; 53(2): 146-152.

Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc 2020; 323: 2052–9.

Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol 2020 Sep; 73(3): 566-574.

Kukla M, Skonieczna- Z˙ ydecka K, Kotfis K, et al. COVID-19, MERS and SARS with concomitant liver injury-systematic review of the existing literature. J Clin Med 2020; 9: 1420.

Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther 2020; 52: 584–99.

Wang Q, Wang Q, Zhao H, et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res 2020; 7:28.

Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327–36.

Parohan M, Yaghoubi S, Seraj A. Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and metaanalysis of retrospective studies. Hepatol Res 2020;10.

Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int 2020;40:321–6.

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA – J Am Med Assoc 2020;323:1061–9.

Downloads

Published

2024-06-06

How to Cite

Güzel, E., Baydar Toprak, O., & Aydin, K. (2024). Hepatotoxicity and Its Impact on Mortality in COVID-19 Patients : Hepatotoxicty in COVID-19. Scientific Reports in Medicine, 1(1), 1–8. https://doi.org/10.37609/srinmed.1

Issue

Section

Research Articles